文献速递骨软组织肉瘤与黑色素瘤

达拉非尼联合曲美替尼治疗BRAF V600突变转移性黑色素瘤的5年结局

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
PubMed 文献 · J Clin Oncol · 2017-10-09

BRF113220研究C部分随机II期长期分析,纳入BRAF V600突变转移性黑色素瘤初治患者,1:1:1随机接受达拉非尼单药、达拉非尼联合曲美替尼1 mg或2 mg方案;达拉非尼单药进展后可交叉至联合组。5年随访显示联合组OS和PFS出现平台期,未观察到新安全信号。

要点

  • 达拉非尼联合曲美替尼2 mg组5年OS率28%、4年OS率30%,4年和5年PFS率均为13%。
  • 基线乳酸脱氢酶正常者5年OS率45%,乳酸脱氢酶正常且转移器官少于3个者5年OS率51%。
  • 延长随访未观察到新的安全信号。

核心结论

  • 达拉非尼联合曲美替尼治疗BRAF V600突变转移性黑色素瘤可获得持续至少5年的长期OS和PFS平台期。

研究设计与样本

  • 随机II期BRF113220研究C部分,BRAF抑制剂初治的BRAF V600突变转移性黑色素瘤患者按1:1:1随机接受达拉非尼150 mg每日两次、达拉非尼150 mg每日两次联合曲美替尼1 mg每日一次或达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次。
  • 达拉非尼单药组患者进展后可交叉至达拉非尼联合曲美替尼2 mg组。
  • 在随访至少5年的患者中分析4年和5年疗效与安全性。

主要发现

  • 达拉非尼联合曲美替尼2 mg组4年OS率30%、5年OS率28%,4年和5年PFS率均为13%,随随访延长似乎趋于稳定。
  • 基线乳酸脱氢酶正常的联合治疗患者5年OS率为45%,基线乳酸脱氢酶正常且转移器官部位少于3个者5年OS率为51%。
  • 延长随访中,达拉非尼联合曲美替尼2 mg组额外1例患者从部分缓解改善为完全缓解。
  • 未观察到新的安全信号。

临床怎么用

  • 该5年分析为BRAF V600突变转移性黑色素瘤中BRAF联合MEK抑制剂治疗迄今最长的随访,显示部分患者可获得持续至少5年的长期OS和PFS平台期。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To report 5-year landmark analysis efficacy and safety outcomes in patients with BRAF V600-mutant metastatic melanoma (MM) who received BRAF inhibitor dabrafenib (D) and MEK inhibitor trametinib (T) combination therapy versus D monotherapy in the randomized phase II BRF113220 study part C. Patients and Methods BRAF inhibitor-naive patients with BRAF V600-mutant MM were randomly assigned 1:1:1 to receive D 150 mg twice a day, D 150 mg twice a day plus T 1 mg once daily, or D 150 mg twice a day plus T 2 mg once daily (D + T 150/2). Patients who received D monotherapy could cross over to D + T 150/2 postprogression. Efficacy and safety were analyzed 4 and 5 years after initiation in patients with ≥ 5 years of follow-up. Results As of October 13, 2016, 18 patients who received D + T 150/2 remained in the study (13 [24%] of 54 enrolled at this dose plus five [11%] of 45 initially administered D who crossed over to D + T). With D + T 150/2, overall survival (OS; 4 years, 30%; 5 years, 28%) and progression-free survival (4 and 5 years, both 13%) appeared to stabilize with extended follow-up. Increased OS was observed in patients who received D + T with baseline normal lactate dehydrogenase (5 years, 45%) and normal lactate dehydrogenase with fewer than three organ sites with metastasis (5 years, 51%). With extended follow-up, one additional patient who received D + T 150/2 improved from a partial to a complete response. No new safety signals were observed. Conclusion This 5-year analysis represents the longest follow-up to date with BRAF + MEK inhibitor combination therapy in BRAF V600-mutant MM. Consistent with trends observed in landmark analyses with shorter follow-up, this therapy elicits durable plateaus of long-term OS and progression-free survival that last ≥ 5 years in some patients with MM.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Long GV, Eroglu Z, Infante J, et al. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol. 2017. PMID: 28991513. doi:10.1200/JCO.2017.74.1025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。